Pipeline

Imsidolimab (ANB019):Anti-IL-36R DEVELOPMENT STAGE & ANTICIPATED MILESTONES THERAPEUTIC INDICATION COMMERCIAL RIGHTS ANTIBODY PROGRAM DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Phase 1 DataPresented atEAACI 2018 GALLOP: Phase 2 Data Presented AtEADV Congress on October 2nd 2021 Top-Line DataAnticipated Q4 2023 HARP: Topline Data Anticipated H2 2022 Generalized PustularPsoriasis ANB032: Anti-BTLA Agonist Inflammatory Diseases HidradenitisSuppurativa Phase 1 Top-LineData AnouncedApril 2022 Rosnilimab (ANB030):Anti-PD-1 Agonist Alopecia Areata Phase 1 Top-LineData AnnouncedNov 2021 AZURE: Phase 2 Initiated Q4 2021 IND Filing of Phase 2 Trialin H2 2022